Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
136 studies found for:    thalidomide myeloma | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide, cyclophosphamide, dexamethasone;   Drug: thalidomide, cyclophosphamide, dexamethasone;   Drug: bortezomib, cyclophosphamide, dexamethasone;   Drug: lenalidomide maintenance;   Drug: lenalidomide plus vorinostat maintenance
2 Recruiting Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide Celgene™
3 Unknown  Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalomid;   Drug: lenalidomide;   Drug: clarithromycin;   Drug: dexamethasone
4 Recruiting Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Procedure: Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI;   Procedure: auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide
5 Unknown  Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
6 Recruiting Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Clarithromycin;   Drug: Thalidomide;   Drug: Cyclophosphamide;   Drug: Dexamethasone
7 Not yet recruiting Efficacy Study Comparing VELCADE DEXAMETHASONE THALIDOMIDE Versus VELCADE CYCLOPHOSPHAMIDE DEXAMETHASONE as Induction Treatment in the Initial Management of Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Thalidomide®;   Drug: Cyclophosphamide;   Drug: Velcade®;   Drug: Dexaméthasone
8 Unknown  Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
9 Recruiting Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Dexamethasone;   Drug: Panobinostat
10 Unknown  Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: thalidomide;   Drug: idarubicin
11 Recruiting Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)
Condition: Myeloma
Interventions: Drug: Thalidomide;   Drug: Lenalidomide;   Behavioral: Questionnaires
12 Unknown  Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib,Pirarubicin,Dexamethasone;   Drug: Thalidomide,Pirarubicin,Dexamethasone
13 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
14 Recruiting Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
Condition: Multiple Myeloma
Intervention: Procedure: Single ASCT with Thalidomide maintenance
15 Recruiting A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Daratumumab;   Drug: Velcade;   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Prednisone;   Drug: Thalidomide;   Drug: Diphenhydramine;   Drug: Acetaminophen
16 Unknown  TCD Followed by autoSCT for Newly Diagnosed MM Patients
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide
17 Unknown  PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Thalidomide;   Drug: Adriamycin;   Drug: Dexamethasone
18 Unknown  Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
Condition: Multiple Myeloma
Intervention: Drug: Thalidomide, cyclophosphamide, dexamethasone, bortezomib
19 Unknown  Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM
Condition: Multiple Myeloma
Intervention: Drug: velcade
20 Recruiting UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma
Condition: Multiple Myeloma
Interventions: Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years